Indeed, increased arousal/activity during the subjective day may be a beneficial side effect, and has a reduction of daytime sleepiness, with no negative impact on night-time sleep has been reported when another A2A antagonist, istradefylline, was administered in the morning to patients with Parkinson’s disease (Suzuki et al., 2017). This evidence concerns the gene IGKV2D-29 and Parkinson disease.